Different Anesthesia Maintain Protocol Effect the Outcome of the Patients
NCT ID: NCT04443946
Last Updated: 2020-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
50 participants
INTERVENTIONAL
2020-06-25
2020-08-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Propofol and Sevoflurane for Catheter-Related Bladder Discomfort
NCT02252445
Comparison of Volatile Anesthetics on Cerebral Oxygenation During Controlled Hypotension
NCT02834845
Comparison Between Target-controlled Infusion of Propofol and Sevoflurane as Maintenance of Anesthesia to Hemodynamic Profile of Renal Transplant Recipient
NCT03214653
Sevoflurane Versus Propofol on Optic Nerve Sheath Diameter During Anesthesia in Steep Trendelenburg Position
NCT04289090
Peri-Operative And Long-Term Cardioprotective Properties Of Sevoflurane In High Risk Patients Undergoing Non-Cardiac Surgery
NCT00336401
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group-P
Group-P: (Propofol group): 5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
Propofol
5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
Group-PAS
Group-PAS: (Propofol and after 20 min adding Sevoflurane group): 2.5 mg kg-1 h-1 propofol were pumped continuously and add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
1% Sevoflurane
add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
Propofol half
2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
Group-PS
Group-PS: (Propofol and Sevoflurane group): 2.5 mg kg-1 h-1 propofol were continuously pumped after endotracheal intubation, and 1% sevoflurane was inhaled continuously at the same time.
1% Sevoflurane continue
1% sevoflurane continued to maintain anesthesia after endotracheal intubation.
Propofol half
2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
Group-S
Group-S: (Sevoflurane group): 2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
2% Sevoflurane
2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
Group-PSu
Group-PSu: (Propofol and Sufentanil group): 5 mg kg-1 h-1 propofol, 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
Propofol
5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
Sufentanil
0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propofol
5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
1% Sevoflurane
add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
1% Sevoflurane continue
1% sevoflurane continued to maintain anesthesia after endotracheal intubation.
Sufentanil
0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
2% Sevoflurane
2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
Propofol half
2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA physical status I, II or III patients
* having elective urological surgery
* operation scheduled to last longer than 1 h
* under necessitating general anesthesia
Exclusion Criteria
* were not able to communicate due to alterations in the level of consciousness, - a history of allergy to opioids
* contraindications inhalational anaesthesia
* family history of malignant hyperthermia
* alcohol or drug abuse
* received central nervous system-active drugs;
* body mass index ≥40 kg/m2
* represent conditions liable to alter the pharmacokinetic and pharmacodynamic behaviors of the intravenous and inhalation anesthetics
* previous head injury, neurologic or psychiatric disease
* any disabling central nervous
* cerebrovascular disease
* current use of psychoactive or anti-convulsive medications
* unstable angina
* manifest congestive heart failure
* airway management was expected to be difficult
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China International Neuroscience Institution
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yanghai Cui
Role: STUDY_CHAIR
China International Neuroscience Institution
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xuanwu hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CINI-AD-20205-19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.